STOCK TITAN

Lantronix (NASDAQ: LTRX) sets $30,000,000 at-the-market stock program

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Lantronix, Inc. entered into a Sales Agreement establishing an at-the-market offering program to sell up to $30,000,000 of its common stock through Needham & Company, LLC and Canaccord Genuity LLC as sales agents. The company may, at its sole discretion, periodically instruct a designated agent on the amount, timing, and minimum price of shares to be sold, and is not obligated to sell any shares.

Sales will be made pursuant to the company’s effective Registration Statement on Form S-3 and a related prospectus supplement. The designated agent will use commercially reasonable efforts to execute sales and will receive a 3% commission on the gross proceeds from each sale. The agreement includes customary representations, covenants, and indemnification provisions, and may be terminated by the company or either sales agent under its terms.

Positive

  • None.

Negative

  • None.
Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
ATM program size $30,000,000 Aggregate offering price of common stock under Sales Agreement
Sales agent commission 3% of gross proceeds Commission rate payable on each sale of shares
Registration statement form Form S-3 (File No. 333-284749) Base shelf used for ATM shares
Effectiveness date of Form S-3 February 19, 2025 Date registration statement was declared effective by SEC
Prospectus supplement date May 8, 2026 Prospectus supplement for ATM program filed under Rule 424(b)
at-the-market offering financial
"with respect to an at-the-market offering program under which the Company may offer and sell"
An at-the-market offering is a method companies use to sell new shares of stock directly into the open market over time, rather than all at once. This allows them to raise money gradually, similar to selling small pieces of a product instead of a large batch. For investors, it means the company can access funding more flexibly, but it may also increase the supply of shares and influence the stock’s price.
Sales Agreement financial
"entered into a Sales Agreement (the “Sales Agreement”) with Needham & Company, LLC"
A sales agreement is a written contract that sets out the terms for selling goods, services, or assets, specifying price, delivery, payment schedule and responsibilities of each side. For investors it matters because it creates a predictable stream of revenue or cash obligations, clarifies timing and risk, and can change a company’s value or forecasts much like a signed order turns a customer’s verbal intent into a firm commitment.
Registration Statement on Form S-3 regulatory
"will be issued pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-284749)"
A registration statement on Form S‑3 is a short, standardized filing a qualified public company uses to register new securities with regulators so they can be sold to investors; think of it as a pre-approved, reusable permission slip that speeds up future offerings. It matters to investors because it lets the company raise money more quickly and cheaply — which can fund growth or pay debt — but may also lead to share dilution or change in ownership, so it affects value and liquidity.
prospectus supplement regulatory
"and a prospectus supplement, dated May 8, 2026, filed with the SEC"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
Rule 415 regulatory
"“at the market offering” as defined in Rule 415 promulgated under the Securities Act"
Rule 415 is a U.S. Securities and Exchange Commission regulation that lets a company register securities ahead of time and then offer them for sale in pieces over an extended period under a “shelf” registration, so offerings can be launched quickly when market conditions suit the issuer. For investors, it signals that management has a ready way to raise capital fast—useful for seizing opportunities but potentially dilutive to existing shareholders, like a company pre-loading a credit line it can tap as needed.
Rule 424(b) regulatory
"filed with the SEC pursuant to Rule 424(b) under the Securities Act"
Rule 424(b) is a U.S. Securities and Exchange Commission requirement that companies file the exact prospectus or prospectus supplement they use to sell securities after a registration statement becomes effective. Think of it as the official posting of the final sales brochure so investors can see the precise terms, risks and use of proceeds; it matters because it ensures transparency, helps investors compare offerings and confirms the issuer complied with disclosure rules.
false 0001114925 0001114925 2026-05-08 2026-05-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 8, 2026

 

 

LANTRONIX, INC.

(Exact Name of Registrant as Specified in Charter)

 

 

Delaware   1-16027   33-0362767
(State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)
         
48 Discovery, Suite 250
Irvine, California 92618
(Address of Principal Executive Offices, including zip code)
         
Registrant’s telephone number, including area code: (949453-3990
 
Not Applicable
(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each Class Trading Symbol Name of each exchange on which registered
Common Stock, $0.0001 par value LTRX The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act.

 

 

 

 

 

 

 

 

Item 1.01Entry into a Material Definitive Agreement

 

On May 8, 2026, Lantronix, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Needham & Company, LLC (“Needham”) and Canaccord Genuity LLC (“Canaccord”), with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $30,000,000 (the “Shares”), through either of Needham and Canaccord, each as its sales agent (together, the “Sales Agents”).

 

Each time the Company wishes to issue and sell Shares under the Sales Agreement, the Company will notify either Sales Agent (the “Designated Agent”) of the number or dollar value of Shares to be issued, the dates on which such sales are anticipated to be made, any minimum price below which sales may not be made and any other sales parameters as the Company deems appropriate. The Company is not obligated to sell any Shares under the Sales Agreement. Subject to the terms of the Sales Agreement, the Designated Agent may sell the Shares by any method that is deemed to be an “at the market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), including sales made through The Nasdaq Capital Market or any other trading market for the Common Stock. The Sales Agents will use commercially reasonable efforts consistent with its normal trading and sales practices. Pursuant to the Sales Agreement, the Company will pay the Designated Agent a commission equal to 3% of the gross proceeds from each sale of Shares sold through the Designated Agent under the Sales Agreement.

 

The Company and/or each Sales Agent may terminate the Sales Agreement in accordance with the terms and conditions set forth therein.

 

Any Shares to be offered and sold under the Sales Agreement will be issued pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-284749), which was filed with the Securities and Exchange Commission (“SEC”) on February 7, 2025 and declared effective by the SEC on February 19, 2025, and a prospectus supplement, dated May 8, 2026, filed with the SEC pursuant to Rule 424(b) under the Securities Act in connection with the offer and sale of the Shares under the Sales Agreement.

 

The Sales Agreement includes customary representations, warranties, conditions, covenants, and indemnification rights and obligations of the Company and the Sales Agents. The foregoing description of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Sales Agreement, a copy of which is filed as Exhibit 1.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated herein by reference.

 

O’Melveny & Myers LLP, counsel to the Company, has issued an opinion to the Company, dated May 8, 2026, relating to the validity of the Shares to be issued and sold pursuant to the Sales Agreement, a copy of which is filed as Exhibit 5.1 to this Current Report.

 

Item 9.01Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit No.   Description
     
1.1*   Sales Agreement, dated as of May 8, 2026, among the Company and the Sales Agents
5.1   Opinion of O’Melveny & Myers LLP
23.1   Consent of O’Melveny & Myers LLP (contained in Exhibit 5.1)
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted schedules and exhibits upon request by the SEC; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedules or exhibits so furnished.

 

 

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

  LANTRONIX, INC.
     
     
Date: May 8, 2026 By:  

/s/ Brent Stringham

     

Brent Stringham

Chief Financial Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 3 

FAQ

What did Lantronix (LTRX) announce in this 8-K filing?

Lantronix entered a Sales Agreement for an at-the-market offering program of up to $30,000,000 in common stock. Shares may be sold from time to time through Needham & Company and Canaccord Genuity as sales agents.

How large is Lantronix’s new at-the-market stock program?

The at-the-market program allows Lantronix to offer and sell up to $30,000,000 of its common stock. Sales can occur over time at the company’s discretion, subject to parameters it sets for each issuance notice.

Which firms are acting as sales agents for Lantronix’s ATM program?

Needham & Company, LLC and Canaccord Genuity LLC are the designated sales agents. Lantronix may choose either firm as the designated agent for particular sales and will pay that agent a commission on gross proceeds from each transaction.

What commission will Lantronix pay on shares sold under this program?

Lantronix will pay the designated sales agent a 3% commission on the gross proceeds from each share sale. This commission is specified in the Sales Agreement governing the at-the-market offering program.

Under what registration is Lantronix selling shares in this ATM program?

Shares sold under the program will be issued pursuant to Lantronix’s effective Registration Statement on Form S-3 (File No. 333-284749) and a prospectus supplement dated May 8, 2026, filed under Rule 424(b).

Is Lantronix required to sell shares under the at-the-market program?

Lantronix is not obligated to sell any shares under the program. The company can decide when and how much to sell, including setting minimum prices and other sale parameters in notices to the sales agents.

Filing Exhibits & Attachments

5 documents